Needham Maintains Buy on Gilead Sciences, Raises Price Target to $200
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice TargetHot
Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $170 to $200.
Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $170 to $200.